Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Harrison

Showing results (21-30 of 218) with videos related to

Pageof 22
Sort By:
Expert Review of Hematology|July 5, 2022
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinibChandan Saha, Claire Harrison
British Journal of Hospital Medicine (London, England : 2005)|March 11, 2009
Full blood countRichard Dillon, Claire Harrison
Hematology (Amsterdam, Netherlands)|February 26, 2015
Essential thrombocythaemiaGeorge Double, Claire Harrison
The Lancet. Haematology|November 5, 2017
Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?Ruben Mesa, Claire Harrison
The Practitioner|May 21, 2005
Managing the erythrocytosesRebecca Sampson, Claire Harrison
Journal of Blood Medicine|January 31, 2012
Emerging treatments for essential thrombocythemiaSteven Okoli, Claire Harrison
Therapeutic Advances in Hematology|April 23, 2013
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for cliniciansClaire Harrison, Alessandro M Vannucchi
Haematologica|December 3, 2015
Myeloproliferative neoplasms and personalized medicine: the perfect match?Jean-Jacques Kiladjian, Claire Harrison
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Experience of Myeloproliferative Neoplasms Guidelines in the United Kingdom: Perspective and International ContextMary Frances McMullin, Claire Harrison
Best Practice & Research. Clinical Haematology|September 6, 2014
How many JAK inhibitors in myelofibrosis?Bruna Velosa Ferreira, Claire Harrison
Pageof 22

Showing results (21-30 of 218) with videos related to

Sort By:
Pageof 22
Expert Review of Hematology|July 5, 2022
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinibChandan Saha, Claire Harrison
British Journal of Hospital Medicine (London, England : 2005)|March 11, 2009
Full blood countRichard Dillon, Claire Harrison
Hematology (Amsterdam, Netherlands)|February 26, 2015
Essential thrombocythaemiaGeorge Double, Claire Harrison
The Lancet. Haematology|November 5, 2017
Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?Ruben Mesa, Claire Harrison
The Practitioner|May 21, 2005
Managing the erythrocytosesRebecca Sampson, Claire Harrison
Journal of Blood Medicine|January 31, 2012
Emerging treatments for essential thrombocythemiaSteven Okoli, Claire Harrison
Therapeutic Advances in Hematology|April 23, 2013
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for cliniciansClaire Harrison, Alessandro M Vannucchi
Haematologica|December 3, 2015
Myeloproliferative neoplasms and personalized medicine: the perfect match?Jean-Jacques Kiladjian, Claire Harrison
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Experience of Myeloproliferative Neoplasms Guidelines in the United Kingdom: Perspective and International ContextMary Frances McMullin, Claire Harrison
Best Practice & Research. Clinical Haematology|September 6, 2014
How many JAK inhibitors in myelofibrosis?Bruna Velosa Ferreira, Claire Harrison
Pageof 22